Author:
Sun Peng,Xue Cong,Li Li-Ren,Shao Cui,An Xin,Thomas Ried,Yang Wei,Deng Ying-Fei,Jiang Wen-Qi,Shi Yan-Xia
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference44 articles.
1. Ho GY, Woodward N, Coward JI (2016) Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol 102:37–46
2. Necchi A, Pond GR, Raggi D et al (2017) Efficacy and safety of gemcitabine plus either taxane or carboplatin in the first-line setting of metastatic urothelial carcinoma: a systematic review and meta-analysis. Clin Genitourin Cancer 15:23–30.e2
3. Sumiyoshi T, Matsumoto K, Utsunomiya N, Segawa T, Muguruma K, Kawakita M (2013) Gemcitabine and cisplatin (GC) or gemcitabine and carboplatin (GCarbo) in patients with metastatic urothelial cancer. Hinyokika Kiyo 59(1):1–6
4. Vassilakopoulou M, de la Motte Rouge T, Colin P et al (2011) Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer 117(24):5500–5508
5. Rai BP, Shelley M, Coles B, Somani B, Nabi G (2012) Surgical management for upper urinary tract transitional cell carcinoma (UUT-TCC): a systematic review. BJU Int 110:1426–1435
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献